Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines

The COVID-19 outbreak was a global pandemic with wide-ranging healthcare implications. Although several mRNA-based vaccines delivered using lipid nanoparticles (LNP) have been approved and demonstrated efficacy at reducing the severity and spread of infection, continued rapid viral evolution and dis...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines (Basel) Vol. 12; no. 3; p. 339
Main Authors:	Xu, Yang, Masuda, Kazuya, Groso, Christine, Hassan, Rick, Zhou, Ziyou, Broderick, Kelsey, Tsuji, Moriya, Tison, Christopher
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01-03-2024 MDPI
Subjects:	adjuvant Antibodies Antigens Biocompatibility Chitosan chitosan nanoparticle COVID-19 COVID-19 vaccines Cytokines Drug delivery systems Drugs Evaluation Health aspects layer-by-layer (LbL) Lipids Materials Microfluidics mRNA Nanomedicine Nanoparticles Outbreaks Pandemics Peptides Proteins Ratios SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 sustained releases T-cells Toxicity Vaccines Vehicles Viral diseases United States United States > US T-cells layer-by-layer (LbL) SARS-CoV-2 chitosan nanoparticle sustained releases adjuvant
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The COVID-19 outbreak was a global pandemic with wide-ranging healthcare implications. Although several mRNA-based vaccines delivered using lipid nanoparticles (LNP) have been approved and demonstrated efficacy at reducing the severity and spread of infection, continued rapid viral evolution and disadvantages currently associated with LNP delivery vehicles (such as toxicity) are driving the design of next-generation SARS-CoV-2 vaccines. Herein, we describe the development of a trimethylated chitosan-based nanoparticle layer-by-layer (LbL) delivery platform for multiple antigens as a scalable and safe COVID-19 vaccine, known as, "LbL-CoV19". These vaccine candidates have been demonstrated to be biocompatible, safe, and effective at stimulating both humoral and cellular responses for protection in preclinical studies. Preliminary results also indicate that LbL-CoV19 can potentially achieve rapid, long-lasting, and broad protection against the SARS-CoV-2 challenge. The "plug-and-play" platform technology is well suited to preparedness for future pandemics and disease outbreaks.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2076-393X 2076-393X
DOI:	10.3390/vaccines12030339